Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebentafusp and Radioembolization in Metastatic Uveal Melanoma
NCT06627244Phase 2Recruiting
- Sponsor
- University of Miami
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Bispecific Antibodies, TCR-Engineered T Cells, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tebentafusp in Uveal melanoma (UM), sponsored by University of Miami. Primary endpoints: Progression Free Survival at 24 months and Treatment-Related Adverse Events at 24 months. Started Feb 2025; status: recruiting.
02
Drugs
tebentafusp
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT06627244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627244.